Related Experiment Videos
Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy
Y Ohtsuka1, K Udaka, Y Yamashiro
1Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Abstract:
Duchenne muscular dystrophy is a lethal and common X-linked recessive disease caused by a defect in dystrophin. Normal myoblast transplantation and dystrophin gene transfer have been expected to correct the deficiency in the muscles, but their clinical application has been hampered by the limited preservation of dystrophin-positive myofibers. In this study we investigated the mechanism for immunologic rejection of normal C57BL/10 (B10) myoblasts transplanted into dystrophin-deficient mdx mice, an animal model of Duchenne muscular dystrophy. We found that mdx mice develop CTL specific for dystrophin itself, which were CD8 dominant and restricted by H-2Kb. We identified several antigenic peptides derived from dystrophin that bind to H-2Kb and are recognized by the mdx anti-B10 CTL. Immunologic tolerance against dystrophin was successfully induced by i.v. injection of these peptides before B10 myoblast transplantation, which resulted in sustained preservation of dystrophin-expressing myofibers in mdx mice. These results demonstrate that dystrophin is antigenic in dystrophin-deficient mice and that immunologic regimen would be necessary to achieve the persistent expression of introduced dystrophin in the muscles of dystrophin-deficient individuals.
Insights
Duchenne muscular dystrophy research shows that the body rejects transplanted cells due to dystrophin. Inducing tolerance to dystrophin peptides successfully preserved muscle cells in mice.
Area of Science:
- Immunology
- Genetics
- Cell Biology
Background:
- Duchenne muscular dystrophy (DMD) is a lethal X-linked disease caused by dystrophin deficiency.
- Current therapies like myoblast transplantation face challenges due to limited preservation of dystrophin-positive myofibers.
- Understanding immune rejection is crucial for effective DMD treatments.
Purpose of the Study:
- To investigate the mechanism of immunologic rejection of normal myoblasts in dystrophin-deficient mdx mice.
- To identify antigenic peptides of dystrophin responsible for immune response.
- To develop strategies for inducing immunologic tolerance to dystrophin.
Main Methods:
- Transplantation of normal C57BL/10 (B10) myoblasts into mdx mice.
- Analysis of cytotoxic T lymphocyte (CTL) response against dystrophin.
- Identification of dystrophin-derived peptides binding to H-2Kb.
- Induction of immunologic tolerance via intravenous peptide injection prior to transplantation.
Main Results:
- Mdx mice developed CD8-dominant CTLs specific for dystrophin, restricted by H-2Kb.
- Specific antigenic peptides derived from dystrophin were identified.
- Pre-transplantation administration of these peptides induced immunologic tolerance.
- Sustained preservation of dystrophin-expressing myofibers was observed in treated mdx mice.
Conclusions:
- Dystrophin is antigenic in dystrophin-deficient mice, triggering an immune response.
- Inducing immunologic tolerance to dystrophin is necessary for sustained expression of introduced dystrophin.
- This study provides a basis for developing immune-modulating strategies for DMD gene and cell therapies.